The Chinese Society of Clinical Oncology (CSCO) Pancreatic Cancer Guidelines recommend nimotuzumab plus gemcitabine as first-line and beyond therapy for advanced KRAS wild-type PDAC (Duan et al., 2024). This evidence concerns the gene KRAS and pancreatic neoplasm.